10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
13.57
+0.76 (5.93%)
At close: Aug 13, 2025, 4:00 PM
13.84
+0.27 (1.99%)
Pre-market: Aug 14, 2025, 9:08 AM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for 10x Genomics stock ranges from a low of $6.50 to a high of $18. The average analyst price target of $13.41 forecasts a -1.18% decrease in the stock price over the next year.
Price Target: $13.41 (-1.18%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Hold | 8 | 8 | 7 | 7 | 7 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Total | 16 | 16 | 15 | 15 | 15 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +25.28% | Aug 12, 2025 |
UBS | UBS | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | -4.20% | Aug 8, 2025 |
Barclays | Barclays | Buy Maintains $13 → $15 | Buy | Maintains | $13 → $15 | +10.54% | Aug 8, 2025 |
B of A Securities | B of A Securities | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | -4.20% | Jun 26, 2025 |
Barclays | Barclays | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | -4.20% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
593.99M
from 610.79M
Decreased by -2.75%
Revenue Next Year
627.26M
from 593.99M
Increased by 5.60%
EPS This Year
-1.22
from -1.52
EPS Next Year
-0.95
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 639.4M | 703.8M | 805.7M | ||
Avg | 594.0M | 627.3M | 687.0M | ||
Low | 560.2M | 569.4M | 614.5M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 4.7% | 18.5% | 28.4% | ||
Avg | -2.7% | 5.6% | 9.5% | ||
Low | -8.3% | -4.1% | -2.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.04 | -0.46 | -0.02 | ||
Avg | -1.22 | -0.95 | -0.71 | ||
Low | -1.54 | -1.23 | -1.11 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.